<DOC>
	<DOCNO>NCT01953679</DOCNO>
	<brief_summary>To compare pharmacodynamic effect 2 continuous dose regimen ulipristal acetate 5.0 10.0 mg-only oral contraception , versus 24/4 day regimen UPA 5.0 mg .</brief_summary>
	<brief_title>Efficacy Study Two Continuous Regimens Oral Daily 5 mg 10 mg Ulipristal Acetate ( UPA ) , Versus Dose 5.0mg UPA 24/4 Days</brief_title>
	<detailed_description />
	<criteria>1 . Women 18 35 year old . 2 . In good health , regular menstrual cycle occur every 2135 day . 1 . If subject postpartum postabortal ( abortion second trimester ) , require two normal menstrual cycle ( 3 menses ) prior screen . 2 . If subject abortion first trimester , require least one menstrual cycle ( two menses ) prior screen . 3 . No current use hormonal contraception intrauterine device least one complete menstrual cycle since stop hormonal contraception start treatment . . No use injectable contraceptive ( e.g . cyclofem depomedroxyprogesterone acetate ) 6 month prior screen unless subject return normal menses since last injection . 4 . Have negative urine pregnancy test admission visit . 5 . Will risk pregnancy . They consistently use nonhormonal method , barrier method every act intercourse time study exit OR surgically sterile male partner vasectomy , must undergone previous tubal ligation , abstinent , samesex relationship control period study exit ( include recovery period ) . 6 . In opinion investigator , willing able follow study requirement , include use study product willing record request information daily diary . 7 . Understand sign IRB approve inform consent form prior screen activity ( include fast blood draw ) . 8 . Will diastolic blood pressure ( BP ) ≤95 mm Hg systolic BP ≤145 mm Hg 5 minute sit position . 9 . BMI &lt; 40 kg/m2 previously undergone bariatric surgery . 10 . Agree participate clinical trial course study . 1 . Women le 18 old 35 year old . 2 . Women menstrual cycle length le 21 35 day ; spontaneous irregular menstrual cycle length intraindividual variation 5 day . . If subject postpartum postabortal ( abortion second trimester ) two normal menstrual cycle ( 3 menses ) prior screen . b . If subject abortion first trimester least one menstrual cycle ( two menses ) prior screen . 3 . Currently pregnant confirm positive highsensitivity urine pregnancy test . 4 . Unwilling use barrier method every act intercourse study exit OR surgically sterile male partner vasectomy , undergone previous tubal ligation , abstinent , samesex relationship control period study exit ( include recovery period ) . 5 . Women plan pregnancy within month study participation . 6 . Currently breastfeed within 30 day discontinue breast feeding , unless woman already menses follow discontinuation breast feeding . 7 . Current use IUD , hormonal contraception within last complete menstrual cycle prior screen . . Use injectable contraceptive ( e.g . cyclofem depomedroxyprogesterone acetate ) 6 month prior screen without subject return normal menses since last injection . 8 . Undiagnosed abnormal genital bleeding . 9 . Known hypersensitivity active substance UPA excipients study treatment . 10 . Anomalies endometrial appearance , TVUS safety lab do screen visit recognize clinically significant investigator . 11 . Subject previous history endometrial ablation . 12 . A clinically significant Pap test abnormality , manage current local national guideline . Women current abnormal Pap ( within last eighteen month ) : 1 . In accordance Bethesda system classification : smear suggestive highgrade precancerous lesion ( ) , include high grade squamous intraepithelial lesion ( HGSILs ) , exclude ; • Women low grade squamous intraepithelial lesion ( LGSIL ) atypical squamous cell undetermined significance ( ASCUS ) /highrisk human papillomavirus ( HPV ) positive , Atypical squamous cell , rule high grade lesion ( ASCH ) may participate evaluate colposcopy biopsy determine evidence lesion severity great cervical intraepithelial neoplasia ( CIN ) I . • Women biopsy find CIN I followup find per standard care ; woman exclude treatment indicate . 2 . In accordance Pap class system : • Women high grade dysplasia exclude . • Women atypical glandular cell undetermined significance ( AGUS ) exclude . • Women low grade dysplasia CIN I interpretation Pap test may participate follow exclusion high grade lesion colposcopic evaluation base Investigator discretion provide appropriate follow accordance local standard . 13 . Has follow know contraindication progestinonly oral contraceptive ( OC ) : 1 . History exist breast cancer , hormone sensitive neoplasia ; 2 . Current history ischemic heart disease stroke pregnant take birth control pills ; 3 . Acute deep venous thrombosis pulmonary embolism ; 4 . Systemic Lupus Erythematosus positive unknown antiphospholipid antibody ; 5 . Benign malignant liver tumor ; 6 . Severe ( decompensated ) cirrhosis . 14 . Hereditary galactose intolerance , Lapp lactase deficiency , glucosegalactose malabsorption . 15 . Known suspected alcoholism drug abuse . 16 . Known HIV infection . 17 . Smoking 15 cigarette per day must evaluate investigator medically qualify designee inclusion base risk factor would increase risk cardiovascular disease ( CVD ) thromboembolism . 18 . Current past deep vein thrombophlebitis thromboembolic disorder . 19 . Current past medically diagnose severe depression , , opinion investigator , could exacerbate use hormonal contraceptive , unless stable antidepressant medication . 20 . Concomitant use medication think interact UPA ( per SPCs ) : 1 . CYP3A4 inducer ( rifampin , barbiturate , carbamazepine , bosentan , felbamate , griseofulvin , oxcarbazepine , phenytoin , St John 's Wort , topiramate ) , 2 . Other hormonal contraceptive include emergency contraception . 21 . Use medication interfere metabolism hormone contraceptive , antibiotic interfere metabolism hormone contraceptive , drug designate FDA Pregnancy Category D X . 22 . Current participation trial investigational medicine device participation past three month start first treatment phase . 23 . Headaches focal neurological symptom . 24 . Have diastolic blood pressure ( BP ) &gt; 95 mm Hg systolic BP &gt; 145 mm Hg 5 minute sit position . 1 . Hypertensive subject treatment control judgment investigator good candidate require waiver participation . 25 . BMI ≥40 kg/m² previously undergone bariatric surgery . 26 . Have issue concern ( judgment investigator ) may compromise safety subject confound reliability compliance information acquire study .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>